Akebia Therapeutics, Inc.

AKBA

$3.07

-12.87% (1 year change)

Avg closing price

Price range

Market Cap

$416 Million

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

$90.1 Million

Total revenue in the last quarter.

Net Income

$-176 Million

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

$-2.97

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

-

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

-0.97x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

$-58.3 Million

Earnings before interest expenses and taxes in the last quarter.

Employees

360

The number of full time employees.

Revenue & Earnings

Balance Sheet

Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

News

Ex-Akebia, Merrimack employees' insider trading convictions stand

Ex-Akebia, Merrimack employees' insider trading convictions stand

The 1st U.S. Circuit Court of Appeals on Friday upheld the convictions and prison sentences of former Akebia Therapeutics Inc and Merrimack Pharmaceuticals Inc employees who were found to have take...

Reuters Reuters, 4 days ago
Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™

Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™

CAMBRIDGE, Mass., Nov. 18, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, toda...

PR Newswire PR Newswire, 7 days ago
Akebia Reports Third Quarter 2020 Financial Results and Recent Business Updates

Akebia Reports Third Quarter 2020 Financial Results and Recent Business Updates

CAMBRIDGE, Mass., Nov. 5, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, to...

PR Newswire PR Newswire, 20 days ago